SHORT-TERM (4 WEEKS) SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) COMPARED TO TENOFOVIR DISOPROXIL FUMARATE (TDF) AND ENTERCAVIR (ETV) IN TREATMENT-NAIVE ADULT PATIENTS WITH HBV-ACLF FROM SOUTH CHINA

被引：0
|
作者：
Peng, Liang [1 ]
Wu, Lina [1 ]
Zhang, Yeqiong [1 ]
Zhu, Xiang [1 ]
Li, Xuejun [1 ]
Xu, Wenxiong [1 ]
Zhen, Limin [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Infect Dis, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
来源：
HEPATOLOGY | 2019年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
492
引用
收藏
页码：311A / 312A
页数：2
相关论文
共 39 条
  • [31] Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
    Li, Juan
    Hu, Chunhua
    Chen, Yi
    Zhang, Rou
    Fu, Shan
    Zhou, Mimi
    Gao, Zhijie
    Fu, Mengjun
    Yan, Taotao
    Yang, Yuan
    Li, Jianzhou
    Liu, Jinfeng
    Chen, Tianyan
    Zhao, Yingren
    He, Yingli
    BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [32] A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results
    Lampertico, Pietro
    Buti, Maria
    Ramji, Alnoor
    Fung, Scott
    Ahn, Sang Hoon
    Chuang, Wan-Long
    Yoon, Seung Kew
    Kao, Jia-Horng
    Chen, Chi-Yi
    Tam, Edward
    Khalili, Mandana
    Bae, Ho
    Ma, Xiaoli
    Tak, Won Young
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Tan, Susanna
    Liu, Yang
    Wu, George
    Subramanian, Mani
    Hann, Hie-Won
    Agarwal, Kosh
    Lim, Young-Suk
    Chan, Henry
    JOURNAL OF HEPATOLOGY, 2020, 73 : S67 - S68
  • [33] IMPACT OF LONG- TERM TREATMENT WITH CONTINUOUS TENOFOVIR ALAFENAMIDE ( TAF) OR AFTER SWITCH FROM TENOFOVIR DISOPROXIL FUMARATE ( TDF) ON HEPATOCELLULAR CARCINOMA ( HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B ( CHB)
    Lim, Young-Suk
    Wong, Grace Lai-Hung C.
    Ahn, Sang Hoon
    Seto, Wai-Kay
    Agarwal, Kosh
    Janssen, Harry L. A.
    Pan, Calvin Q.
    Chuang, Wan Long
    Fung, Scott K.
    Shalimar
    Brunetto, Maurizia R.
    Hui, Aric Josun
    Chang, Ting-Tsung
    Lim, Seng Gee
    Abramov, Frida
    Flaherty, John F.
    Wang, Hongyuan
    Yee, Leland J.
    Kao, Jia-Horng
    Marcellin, Patrick
    Gane, Edward J.
    Buti, Maria
    HEPATOLOGY, 2023, 78 : S523 - S526
  • [34] A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results
    Lampertico, Pietro
    Buti, Maria
    Fung, Scott
    Ahn, Sang Hoon
    Chuang, Wan-Long
    Tak, Won Young
    Ramji, Alnoor
    Chen, Chi-Yi
    Tam, Edward
    Bae, Ho
    Ma, Xiaoli
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey
    Feierbach, Becket
    Wu, George
    Suri, Vithika
    Subramanian, G. Mani
    Oberle, Corinna
    Huy Trinh
    Yoon, Seung-Kew
    Agarwal, Kosh
    Lim, Young-Suk
    Chan, Henry L. Y.
    SWISS MEDICAL WEEKLY, 2019, : 25S - 25S
  • [35] A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results
    Lampertico, Pietro
    Buti, Maria
    Fung, Scott
    Ahn, Sang Hoon
    Chuang, Wan-Long
    Ramji, Alnoor
    Tak, Won Young
    Chen, Chiyi
    Tam, Edward
    Bae, Ho
    Ma, Xiaoli
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey
    Feierbach, Becket
    Wu, George
    Suri, Vithika
    Subramanian, Mani
    Trinh, Huy N.
    Yoon, Seung Kew
    Agarwal, Kosh
    Lim, Young-Suk
    Chan, Henry
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E470 - E471
  • [36] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2
    Lim, Young-Suk
    Lin, Chun-Yen
    Heo, Jeong
    Bae, Ho
    Chuang, Wan-Long
    Yin, Tak
    Tsang, Owen
    Fournier, Claire
    Hui, Aric Josun
    Trinh, Huy
    Chan, Carol Yee Kwan
    Tan, Susanna K.
    Zhao, Yang
    Flaherty, John F.
    Suri, Vithika
    Gaggar, Anuj
    Brainard, Dianna M.
    Ryder, Stephen
    La Janssen, Harry
    GUT, 2021, 70 : A77 - A77
  • [37] LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS
    Heathcote, E. Jenny
    Gane, Edward J.
    deMan, Robert A.
    Chan, Sing
    George, Jacob
    Tsai, Naoky C. S. C.
    Marcellin, Patrick
    Snow-Lampart, Andrea
    Coombs, Derek H.
    Mondou, Elsa
    Anderson, Jane
    HEPATOLOGY, 2010, 52 (04) : 556A - 557A
  • [38] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
    Gallant, J.
    Orkin, C.
    Molina, J-M
    Negredo, E.
    Antinori, A.
    Mills, A.
    Eron, J.
    Reynes, J.
    van Landuyt, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    HIV MEDICINE, 2018, 19 : S32 - S32
  • [39] Significantly lower incidence of lipid abnormalities and neuropsychiatric adverse events (AEs) with rilpivirine (RPV) compared to efavirenz (EFV) in treatment-naive HIV-1-infected adult patients: emtricitabine/tenofovir DF (FTC/TDF) subset from pooled analysis of the Phase III ECHO and THRIVE trials at 48 weeks
    Mills, A.
    Vanveggel, S.
    Boven, K.
    Guyer, B.
    Chuck, S. K.
    ANTIVIRAL THERAPY, 2011, 16 : A63 - A64
1234